US-based, direct-to-consumer telehealth brand Lttl reported on Friday that it has launched a new site that specialises in personalised GLP-1 weight management, longevity protocols, and microdosed therapy.

Lttl said it allows patients to connect with licensed healthcare providers through a state-of-the-art telehealth platform. These providers review each patient's history, evaluate their goals, and develop treatment plans tailored specifically to their individual clinical profile.

These treatment plans include GLP-1 weight loss treatment with Semaglutide and Tirzepatide formulas. These compounds are also available in microdose formulations designed to support energy, metabolism, and everyday performance. Lttl says that it also offers tailored treatments to support energy, metabolism, and healthy aging. And the brand's broad peptide selection offers support for recovery, longevity, gut health, cognition, and sleep. It adds that every plan is designed and prescribed by a licensed physician, and tailored to each patient's goals, history, and progress with unlimited 24/7 support.

The company added that it partners exclusively with state-licensed 503a compounding pharmacies that source their active pharmaceutical ingredients (APIs) from FDA-registered manufacturers. Those active pharmaceutical ingredients are accompanied by a valid Certificate of Analysis, which verifies the APIs' quality and compliance with regulatory standards.